Your browser doesn't support javascript.
loading
Artificial Bone Graft Substitutes for Curettage of Benign and Low-Grade Malignant Bone Tumors: Clinical and Radiological Experience with Cerasorb.
Wittig, Ulrike Susanne; Friesenbichler, Jörg; Liegl-Atzwanger, Bernadette; Igrec, Jasminka; Andreou, Dimosthenis; Leithner, Andreas; Scheipl, Susanne.
Afiliação
  • Wittig US; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.
  • Friesenbichler J; Department of Trauma Surgery, Wiener Neustadt State Hospital, Wiener Neustadt, Austria.
  • Liegl-Atzwanger B; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.
  • Igrec J; Diagnostic and Research Center for Molecular Biomedicine, Diagnostic and Research Center for Pathology, Medical University of Graz, Graz, Austria.
  • Andreou D; Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.
  • Leithner A; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.
  • Scheipl S; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.
Indian J Orthop ; 57(9): 1409-1414, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37609019
Background: Artificial bone graft substitutes (ABGS) for curettage of bone tumors are becoming increasingly popular. The aim of this retrospective analysis was to determine the efficacy of the ABGS Cerasorb (Curasan-AG, Kleinostheim, Germany), a beta-tricalcium phosphate (beta-TCP), concerning resorption profile, bone healing, and remodeling after surgery and to evaluate potential complications. Methods: Forty-three patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb between 2018 and 2021 and included in the final analysis. Clinical follow-up exams with X-rays in two planes were performed 6 weeks, 3 months, 6 months, and 1 year after surgery. Results: After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients. Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial. In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within 6 weeks after primary surgery. Conclusion: In conclusion, the beta-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption. Level of Evidence: III; retrospective cohort study.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Indian J Orthop Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Indian J Orthop Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Áustria